DISABILITY PROGRESSION IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCE DISEASE ACTIVITY DESPITE PREVIOUS DISEASE MODIFYING THERAPY

DISABILITY PROGRESSION IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCE DISEASE ACTIVITY DESPITE PREVIOUS DISEASE MODIFYING THERAPY

Bibliographic Details
Main Authors:	Hettle, R, Murphy, J, Eckert, B
Format:	Journal article
Published:	2011

Similar Items

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
by: Lesage, E, et al.
Published: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
by: E. Lesage, et al.
Published: (2010-01-01)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
by: Arkadiusz Bydliński, et al.
Published: (2024-05-01)

Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)
by: Silvia Ciotti, et al.
Published: (2021-02-01)

Increased Level of Caspase-1 in the Serum of Relapsing-remitting Multiple Sclerosis (RRMS) Patients
by: Masoumeh Beheshti, et al.
Published: (2020-10-01)

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments
by: Gutemberg Augusto Cruz dos Santos, et al.
Published: (2022-12-01)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
by: Fabricio Gonz&aacute;lez-Andrade, et al.
Published: (2010-07-01)

Serum Matrix Metalloproteinase-9 Level and Previous Disease Activity in Relapsing-Remitting Multiple Sclerosis
by: Eman Hamdy, et al.
Published: (2023-01-01)

Multiple Sclerosis Relapsing Remitting Progressive Type
by: Nora Fitri, et al.
Published: (2020-12-01)

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01)

008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
by: Steve Vucic, et al.
Published: (2021-08-01)

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
by: Georgios Tsivgoulis, et al.
Published: (2015-01-01)

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
by: Katline Metzger-Peter, et al.
Published: (2020-06-01)

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents
by: Alessandro Finkelsztejn, et al.
Published: (2012-10-01)

Early clinical predictors of disease progression in relapsing-remitting multiple sclerosis: the Oxford UK cohort
by: Wakerley, B, et al.
Published: (2011)

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
by: Arnfin Bergmann, et al.
Published: (2021-08-01)

Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing–Remitting Multiple Sclerosis
by: Foziah Jabbar Gossab Alshamrani, et al.
Published: (2024-10-01)

Interferons in relapsing remitting multiple sclerosis.
by: Goodin, D
Published: (2003)

Does the type of disease-modifying drugs impact on the quality of life in patients with relapsing-remitting multiple sclerosis?
by: Amirreza Naseri, et al.
Published: (2020-09-01)

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
by: Iciar Martínez-López, et al.
Published: (2020-04-01)

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
by: Oscar Fernández, et al.
Published: (2017-01-01)

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
by: J. Nicholas, et al.
Published: (2012-04-01)

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
by: J. Nicholas, et al.
Published: (2012-05-01)

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab
by: Y. C. Wang, et al.
Published: (2011-01-01)

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis
by: Ahmad, H, et al.
Published: (2018)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
by: S. Migliore, et al.
Published: (2017-01-01)

Red cell distribution width as a predictor of disability in relapsing-remitting multiple sclerosis
by: R. Rocha, et al.
Published: (2022-04-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
by: V. Casado, et al.
Published: (2021-07-01)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
by: Cifelli, A, et al.
Published: (2003)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
by: Wylezinska, M, et al.
Published: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Cognitive impairment in relapsing remitting Multiple Sclerosis
by: Saška Roškar
Published: (2003-06-01)

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
by: Emanuele D’Amico, et al.
Published: (2019-09-01)

Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis
by: Linda Östlundh, et al.
Published: (2023-07-01)

Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
by: Anna Bizoń, et al.
Published: (2022-12-01)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
by: Daniel Kantor, et al.
Published: (2023-03-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01)